Agenus Inc. buy tbackenh
Summary
This prediction ended on 03.06.16 with a price of €3.97. The BUY prediction by tbackenh finished with a performance of 7.85%. tbackenh has 50% into this predictionAgenus is a biotechnology company focused on developing immunotherapies to treat cancer and other diseases. The company's product pipeline includes checkpoint inhibitors, which work by blocking proteins that help cancer cells evade detection by the immune system, as well as other immunotherapies designed to stimulate the body's immune response to tumors. Agenus has collaborations with large pharmaceutical companies including Merck, Incyte, and Gilead, and is actively working on bringing its products to market through clinical trials and regulatory approval. The company is listed on the NASDAQ stock exchange under the ticker symbol AGEN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Agenus Inc. | - | - | - | - |
| iShares Core DAX® | 1.280% | 1.320% | 13.605% | 15.782% |
| iShares Nasdaq 100 | -2.457% | -5.192% | 25.941% | 38.434% |
| iShares Nikkei 225® | -2.006% | -1.389% | 8.973% | 6.570% |
| iShares S&P 500 | -0.662% | -1.884% | 23.684% | 39.611% |
Comments by tbackenh for this prediction
In the thread Agenus Inc. diskutieren
Agenus Inc.
Aktuell befindet sich das Unternehmen kurz davor, die frühen klinischen Studien für zwei wichtige Antikörpermedikamente zu beginnen. AGEN1884 und INCAGN1876 sollten nicht allzu lange brauchen, um Top-Umsätze zu erzielen wie ähnliche Produkte in der jüngeren Vergangenheit. Nach dem Kursverfall überwiegen klar die Chancen auf eine Erholung. Für mich ein interessanter Kauf!